GlassScriptPhysician profile
Scott V Mcrae
NPI 1144390006
$1,925.04
in general payments reported to CMS, 2019-2025
21 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $93.56 · 2021: $309 · 2022: $174 · 2023: $440 · 2024: $184 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.02 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.01 | 2019-2025 | |
| Gilead Sciences, INC. | $238.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $153.76 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $150.40 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $148.79 | 2019-2025 | Entyvio, Eohilia |
| Laborie Medical Technologies Corp. | $116.43 | 2023 | |
| Medtronic, INC. | $62.14 | 2023 | Pillcam |
| Intercept Pharmaceuticals, INC. | $57.50 | 2022-2025 | |
| Braintree Laboratories, INC. | $54.84 | 2021 | |
| Olympus America INC. | $45.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.65 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $40.07 | 2024-2025 | Zenpep |
| Conmed Corporation | $34.90 | 2021-2023 | Conmed Dilation, Conmed Generators, Conmed Polypectomy |
| Phathom Pharmaceuticals, INC. | $31.67 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $30.95 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29.66 | 2025 | |
| Pfizer INC. | $28.60 | 2019 | |
| Ucb, INC. | $26.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2019 | |
| Shire North American Group INC | $17.02 | 2019 | |
| Echosens North America, INC. | $5.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mcrae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.